Exonate has appointed Olav Hellebø as Chief Executive Officer (CEO). Hellebø brings extensive business and scientific ...

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and ...

Ipsen is set to acquire Memo Therapeutics in a deal worth more than €700m EUR that is focused on potravitug, a phase 2 ...

Alignment is not proven by whether teams are coordinated, it is proven by whether their combined efforts are sustained ...

Teva Pharmaceutical has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval ...

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal worth around $10.0bn. Crinetics is a global ...

The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates ...

Novartis is set to acquire Myricx Bio, paying $1.1bn upfront, with up to $400m in potential milestone payments. The acquisition would strengthen Novartis’ oncology pipeline and advance next-generation ...

Launching prescription medicines excellently – achieving optimal commercial performance that reflects a medicine’s value and ...

Klick Health, a global, independent commercialisation partner for life sciences, has acquired Oxford PharmaGenesis, a ...